Skip to content

Dr. Robert Langer

Ron Levy is one of the pioneers of the immuno-oncology field. He was the Chief of Oncology at Stanford Medical School for over 20 years. He pioneered the use of CD 20 (Rituximab) as the first monoclonal antibody for treatment of lymphoma. Ron has also been involved as co-founder of Biogen-Idec (BIIB), and scientific advisory board member for Kite Pharma (acquired by Gilead for $12B) and Five Prime Therapeutics. He received his bachelor’s degree from Harvard University and MD from Stanford University.

Back To Top